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Abstract
Background: Trials of intermittent preventive treatment in infants (IPTi) and children (IPTc) have shown promising results in
reducing malaria episodes but with varying efficacy and cost-effectiveness. The effects of different intervention and setting
characteristics are not well known. We simulate the effects of the different target age groups and delivery channels,
seasonal or year-round delivery, transmission intensity, seasonality, proportions of malaria fevers treated and drug
characteristics.
Methods: We use a dynamic, individual-based simulation model of Plasmodium falciparum malaria epidemiology,
antimalarial drug action and case management to simulate DALYs averted and the cost per DALY averted by IPTi and IPTc.
IPT cost components were estimated from economic studies alongside trials.
Results: IPTi and IPTc were predicted to be cost-effective in most of the scenarios modelled. The cost-effectiveness is driven
by the impact on DALYs, particularly for IPTc, and the low costs, particularly for IPTi which uses the existing delivery strategy,
EPI. Cost-effectiveness was predicted to decrease with low transmission, badly timed seasonal delivery in a seasonal setting,
short-acting and more expensive drugs, high frequencies of drug resistance and high levels of treatment of malaria fevers.
Seasonal delivery was more cost-effective in seasonal settings, and year-round in constant transmission settings. The
difference was more pronounced for IPTc than IPTi due to the different proportions of fixed costs and also different
assumed drug spacing during the transmission season. The number of DALYs averted was predicted to decrease as a target
five-year age-band for IPTc was shifted from children under 5 years into older ages, except at low transmission intensities.
Conclusions: Modelling can extend the information available by predicting impact and cost-effectiveness for scenarios, for
outcomes and for multiple strategies where, for practical reasons, trials cannot be carried out. Both IPTi and IPTc are
generally cost-effective but could be rendered cost-ineffective by characteristics of the setting, drug or implementation.
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Introduction
An estimated 250 million episodes of malaria led to nearly
one million deaths in 2008, the brunt of which was borne by
young children and infants in sub-Saharan Africa [1]. In
addition to its impact on the health of individuals, malaria
places considerable costs on households [2–4], communities [5]
and nations [6,7].
Intermittent preventive treatment in infants (IPTi) and children
(IPTc) have received attention in recent years as potential
interventions to reduce malaria morbidity and mortality. Both
follow the same strategy: to deliver a full course of an anti-malarial
treatment to a population at risk at specified time points whether
or not they are known to be infected [8,9]. Both aim to retain the
benefits of chemoprophylaxis whilst avoiding the acceleration of
drug resistance or impairing the development of acquired
immunity [9–11].
The two interventions differ in their target age group and
delivery system. By targeting infants under 12 months, IPTi is able
to benefit from the existing delivery strategy of the Expanded
Programme on Immunization (EPI). The delivery of IPTi involves
training health workers to administer a dose of an antimalarial
drug during routine scheduled visits in health facilities and to
document this using modified EPI monitoring tools [12,13]. IPTc
has targeted mainly children up to the age of five years [14–22]
but also older age groups [23] and school children [24–27]. In
children under five years, IPTc has no established delivery system
but studies have used community health workers and outreach
clinics to provide doses for the target age-group [20,21]. Studies
have mostly focused on IPTc as a seasonal intervention in settings
with seasonal transmission.
Both IPTi and IPTc have been found to reduce clinical
incidence. Several clinical trials in different settings have shown
IPTi to be effective against malaria to varying degrees [28–33]. A
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sulfadoxine-pyrimethamine (SP) estimated a 30% (95% CI 20%,
39%) protective efficacy (PE) against clinical malaria and 38%
(13%, 56%) PE against hospital admissions with malaria parasites
[34]. Studies using drugs other than SP found that efficacious,
long-lasting drugs had a greater PE than shorter-acting drugs or
drugs with high levels of resistance [35,36]. Seasonal IPTc with
combinations of SP, artesunate (AS) and amodiaquine (AQ) has
been seen to reduce the incidence of clinical malaria in children
under the age of five years in settings with a short malaria
transmission season [14,15,17,37] and where the transmission
season is longer [19,38]. A pooled analysis of IPTc trials estimated
a 75% (64%, 83%) protective efficacy against malaria episodes
during the intervention period [39]. The trials were not designed
to detect an impact on mortality due to the very large sample sizes
required.
There have been costing and cost-effectiveness studies alongside
many of the IPT trials [12,13,21,40–42]. In nearly all of the studies
where IPT was efficacious, it was highly cost-effective. In sites
where IPTi had a significant effect, the cost per malaria episode
averted for IPTi-SP ranged from US$ 1.36 to 4.03 based on trial
specific data [40]. For IPTi using more expensive antimalarials,
the cost per treated episode averted ranged from US$4.62 using
AQAS to US$ 18.56 using mefloquine (MQ) [40]. For seasonal
IPTc, a trial in Ghana estimated the costs per episode averted for
three different regimens administered over the six month
transmission period. Bimonthly SP cost $105 ($75, $157) per
treated episode averted, bimonthly ASAQ was $212 ($127, $399)
and monthly ASAQ was US$68 ($62, $75) [42]. The estimates for
district scale-up fell to $28, $60 and $22 respectively [42]. In
addition, where efficacious, IPT reduced health system costs and
showed significant savings to households from malaria episodes
averted.
The variations in efficacy and cost-effectiveness between trials
stem not only from the choice of drug but also from the different
setting and trial characteristics such as transmission intensity,
timing of delivery, local costs and use of other interventions. This
raises questions that the trials were not designed to answer such as
the effects of the different characteristics, the impact on severe
malaria and mortality, and the limits beyond which IPT is no
longer cost-effective [43–47]. It is not feasible to carry out a large
number of large field trials of different combinations to determine
the impact of each factor on different malariological outcomes.
Where data cannot be collected, mathematical modelling can be
used to provide predictions.
In this paper, we use a comprehensive model of Plasmodium
falciparum epidemiology and economics [48] to investigate the
influence of different variables on the effects and the cost-
effectiveness of IPT in preventing disability adjusted life years
(DALYs): target age group and delivery channel, seasonal or year-
round delivery, transmission intensity and seasonality of the
setting, the timing of the first IPT dose for seasonal delivery,
different coverage levels of treatment for malaria fevers and the
impact of drug resistance. We also predict the impact of IPT on
transmission intensity.
Methods
The simulation model
We use a dynamic, individual-based, stochastic simulation of
malaria epidemiology which has been described elsewhere [48].
Briefly, there is a simulated population of humans who are
updated at each five-day time step via model components
representing new infections, parasite densities, acquired immunity,
uncomplicated and severe episodes, direct and indirect malaria
mortality, infectivity to mosquitoes and case management. This
study does not include simulation of anaemia. The course of
parasite densities over an infection are described by averaged
empirical data [49]. Immunity to asexual parasites is derived from
a combination of cumulative exposure to both inoculations and
parasite densities, and maternal immunity [49]. The inclusion of
acquired immunity allows us to model potential effects of IPT on
immunity through loss of exposure and the inclusion of infectivity
captures potential effects on transmission intensity. The probabil-
ity of a clinical attack of malaria depends on the current parasite
density and a pyrogenic threshold [50]. The pyrogenic threshold
responds dynamically to recent parasite load, increasing or
saturating with exposure to parasites and decaying with time,
and thus is individual-and time- specific. Severe malaria can arise
in two ways, either as a result of overwhelming parasite densities or
through uncomplicated malaria with concurrent non-malaria co-
morbidity [51]. Mortality can be either direct (following severe
malaria) or indirect (uncomplicated malaria in conjunction with
co-morbidity, or during the neonatal period as a result of maternal
infection). Thus the model does not assume a fixed case fatality
rate for malaria episodes, but makes a number of intermediary
assumptions to model pathways from an acute episode to death.
The parameter values for each of the components of the model
were estimated by fitting to data from a total of 61 malaria field
studies of different aspects of malaria epidemiology [52] and are
reported elsewhere [53]. The model has been validated using age-
specific results from six IPTi trials with SP [53]. It has
subsequently been validated against trials of IPTc [17,19].
Simulation strategy
We simulate seasonal and non-seasonal delivery for both IPTi
and IPTc to allow us to separate the effects of seasonal delivery
from the combination of the intervention target age-group and
delivery channel. We simulate two contrasting seasonal patterns
(constant and highly seasonal transmission) and two IPT drugs (SP
and ASAQ). These four factors have two levels each making a set
of 16 baseline intervention scenarios (Table 1). For each of these
scenarios, we then investigated the impact of varying levels of drug
resistance, transmission intensity, the timing of seasonal imple-
mentation and the proportion of malaria fevers which are
effectively treated (Table 2). We also simulate the impact of either
widening the target IPTc age group or shifting it into older ages.
We simulate 10 seeds for each scenario each of a population of
100,000 individuals aged up to 90 years over ten years from the
introduction of the IPT programme.
Delivery frequency and modality of IPTc and IPTi in the
baseline scenarios
For IPTi, the EPI visits were assumed to be scheduled at 3, 4
and 9 months of age (Table 1). For seasonal delivery, only infants
who were presented for their EPI visits during the short
transmission season received the doses and so no infant would
receive all three doses.
The baseline target IPTc age group was 3 months to 5 years.
We model IPTc delivery either every two months throughout the
year or as three IPTc doses at monthly intervals during the malaria
season. IPTc was assumed to be delivered, and costed, via
community health workers (CHWs) who were individuals in the
community given a small financial incentive to deliver IPTc.
Studies in The Gambia and Ghana found that CHWs were able to
reach more children under five years than outreach services linked
to EPI [20,21]. The timing of the doses relative to the start of the
season for seasonal delivery is shown in Figure 1. In the baseline
Cost-Effectiveness of IPTi and IPTc
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for 3 doses) [53] and that IPTc coverage was 84% per dose for
CHW [20,21]. ASAQ includes 3 tablets to be taken on 3
consecutive days: we assumed that compliance with the tablets
given to carers to administer at home was 100%. Compliance has
been reported to be 88% to 99% in trial settings [18,20,22,38].
IPT drugs
We simulate two drugs, ASAQ and SP, both of which have
previously been chosen for IPT trials. They demonstrate different
characteristics: SP is a cheap, long-acting drug with high levels of
resistance whereas ASAQ is a more expensive, shorter-acting drug
currently meeting less drug resistance. We recognise that there are
other potential IPT drug candidates that we have not included,
nevertheless, the contrasting characteristics of these two drugs
demonstrate the substantive effects.
A simple model component for antimalarial drug action [53]
was adapted from Hastings and Watkins [54] and incorporated
into the simulations. Briefly, the ability of SP and ASAQ to both
clear existing infections and to prevent new infections becoming
established depends on the genotype of the infection. Infections
are assigned genotypes randomly according to assumed frequen-
cies (Table 2). Hastings and Watkins quantify the chances of failing
treatment with correct dosing of SP for wildtype infections and
infections with single, double and triple dihydrofolate reductase
(dhfr) mutations conferring resistance at 0, 0, 0, 50% respectively
while periods of prophylactic effects are 52, 12, 12, 2 days [54].
We round these to the five-day timesteps used by the model. For
ASAQ, we assume that all infections are cleared and that for AQ-
sensitive infections, the prophylactic period is assumed to be 15
days and for AQ-resistant infections, 0 days [55–57].
Intervention costs
The costs (Table 3) were based on economic evaluations
conducted in a range of IPTi and IPTc sites [13,40,42,58]. Similar
cost categories and methodological costing approaches were used
for both interventions covering district costs associated with
community sensitization, behaviour change and communication,
drug distribution and administration, training and supervision.
The costs were identified from components of trial budgets and
primary data on resource use. Care was taken to exclude costs
relating specifically to research or to a trial environment. We
costed IPTc only in the baseline target age group of 3 months to 5
years since while schools may be used for some age groups [26],
the delivery mechanisms for others are unclear. Costs of
incentivising the CHW who delivers the IPTc drugs to an
assumed 250 children were included in administration costs to
reflect an allowance of approximately US$10 a month during the
months of administration [20,21]. The costs of the IPT drugs were
based on prices presented on the International Drug Price
Indicators List [59]: SP was assumed to cost $0.02 per dose and
ASAQ $0.36 per course of three tablets. Remainder fractions of
Table 1. Set of baseline intervention scenarios.
Variable Levels IPTi IPTc
Target ages 3, 4 and 9 months 3 months to 5 years
Period of delivery Year-round At 3, 4 and 9 months through EPI Bi-monthly doses via CHW
Seasonal At 3, 4 and 9 months if EPI visits coincide
with malaria season
Monthly doses for 3 months via CHW
IPT coverage per dose 95% 84%
IPT drug SP SP
ASAQ ASAQ
Seasonality of setting No seasonality Constant transmission Constant transmission
Highly seasonal
1 Niakhar Niakhar
EPI: Expanded Programme on Immunization CHW: community health workers.
1The highly seasonal pattern of transmission was taken from Niakhar, Senegal [89] where transmission is concentrated into three months of the year.
doi:10.1371/journal.pone.0018391.t001
Table 2. Model inputs varied in the simulations.
Variable Description Levels
Transmission intensity Infected bites per person per year prior to the
introduction of IPT
1, 6, 21 (baseline), 50
Case-management coverage Proportion of fevers treated per 5 day timestep 0, 4 (baseline), 10, 30, 50, 75 and 100%
Timing of seasonal delivery of IPT In seasonal setting only The period of delivery is shifted up to 4 months earlier or later than the
baseline scenarios (Figure 1)
Frequency of drug resistance Percentage of wildtype infections SP*: 0, 20, 40, 60, 80 (baseline), 100%
ASAQ: 90% wildtype, 10% fully resistant to AQ
Target ages for IPTc Widening age groups 3 m–5 y, 3 m–10 y, 3 m–15 y,…3 m–35 y,3 m–40 y
Shifting age groups 3 m–5 y, 2.5–7.5 y,5–10 y,7.5–12.5 y,…35–40 y
*For SP, the remainder is divided 50:50 between single/double and triple dhfr mutations.
doi:10.1371/journal.pone.0018391.t002
Cost-Effectiveness of IPTi and IPTc
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households was found to be negligible and therefore excluded [21].
The cost per dose of IPT drugs, delivery and administration
remained unchanged for each dose irrespective of the number of
doses given. The costs of training, sensitization and a minimum
level of supervision were assumed to be fixed over the course of the
year and therefore the unit cost per dose of IPT year-round was
less than that of seasonal delivery. This assumption was based on
trial activity and discussions with implementers about how IPT
would be delivered if introduced as part of routine activity.
Whether the doses were given throughout the year or concen-
trated in three months, a one-off training would be held each year
for those involved in delivering IPT. Sensitization activities would
involve the same resources even though the message about IPT
frequency would be different. Supervision was assumed to be semi-
fixed in that a minimum would be required and so it would be
slightly more intense for seasonal than year-round IPT. The costs
were calculated in US$2006 to be comparable with previous costs
for case management [60], all costs were then inflated to US$2009
using US dollar inflation rates [61].
Potential cost savings of IPT
The simulations include direct malaria treatment costs to both
the providers and households. We do not include indirect costs
such as potential earnings forgone by the carers [60]. The health
system adopted is based on a previously used model [62] with
artemisinin combination therapy as the first-line treatment with
low rates of access. The case management costs assumed have
been previously published [60].
Cost-effectiveness
The approach adopted follows previous work on modelling
the cost-effectiveness of malaria vaccines [60,63] and follows
standard practices [64,65]. The primary epidemiological out-
Figure 1. Timing of seasonal delivery in the baseline scenarios. The shaded area is the 3 month period of IPT delivery. The seasonal pattern
follows that reported for Niakhar, Senegal [89].
doi:10.1371/journal.pone.0018391.g001
Table 3. Unit costs per dose (USD 2009).
IPTc
1 IPTi
seasonal year-round seasonal year-round
SP ASAQ SP ASAQ SP ASAQ SP ASAQ
Cost of IPT drugs 0.02 0.36 0.02 0.36 0.02 0.36 0.02 0.36
Drug dispensing and supplies 0.20 0.20 0.20 0.20 0.01 0.01 0.01 0.01
Delivery of drugs 0.09 0.09 0.09 0.09 0.06 0.06 0.06 0.06
Supervision 0.21 0.21 0.15 0.15 0.01 0.01 0.01 0.01
Training 0.14 0.14 0.07 0.07 0.13 0.13 0.04 0.04
Sensitization 0.03 0.03 0.02 0.02 0.03 0.03 0.01 0.01
Total 0.69 0.97 0.56 0.90 0.27 0.61 0.16 0.50
1IPTc for baseline age group of 3 months to 5 years using village health workers.
doi:10.1371/journal.pone.0018391.t003
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comparable, summary measure of the burden. One DALY
represents a year of healthy life lost. Years of life lived with
disability were calculated on the basis of the duration of disability
and the disability weights for the different malaria attributable
disease conditions obtained from the Global Burden of Disease
study [66]. DALYs were calculated assuming age-specific life
expectancies typical for an East African setting with low malaria
transmission [60,63] and with no age weighting to follow
standard cost-effectiveness practices [67]. Future costs and health
gains are discounted at 3%. The cost-effectiveness ratios are to be
interpreted as incremental cost-effectiveness ratios (ICERs) of
implementing the interventions in the simulated scenarios relative
to a do nothing scenario which corresponds to maintaining only
case management.
Recognising that the selection of cost-effectiveness thresholds
in published literature is subjective [68], we refer to the
conservative cut off point of US$ 223 per DALY averted to
reflect a cost-effective intervention, and US$ 37 per DALY
averted to reflect a highly cost-effective intervention. These
thresholds are based on US$ 150 and US$ 25 thresholds
suggested by the World Bank in 1993 [68,69] and inflated to
their 2009 equivalent.
Results
Both IPTc and IPTi were cost-effective in a wide range of
simulated settings.
Seasonal and year-round delivery in seasonal and
perennial transmission settings
The effect of seasonal delivery depends on the seasonal pattern
of transmission. In the constant transmission setting (Figure 2 top
row), year-round delivery averts a greater number of DALYs than
seasonal delivery for both IPTi and IPTc (Figure 2 a and c). Year-
round delivery is also more cost-effective than seasonal delivery,
substantially so for IPTc whereas for IPTi the difference is less
pronounced. As well as the different unit costs, the different
spacing of doses in combination with the assumed prophylactic
periods contribute to year-round IPTc delivery being more cost-
effective. For IPTi, the numbers of DALYs averted are
proportional to the numbers of doses administered.
In the highly seasonal setting (Figure 2, bottom row), the
numbers of DALYs averted are much closer for seasonal and year-
round delivery since there are few episodes outside the main
transmission season. In this case, seasonal delivery is more cost-
effective than year-round for both IPTi and IPTc due to the lower
total costs.
Transmission intensity and target age group
We focus on the lower end of the range of transmission because
interest lies in determining where IPT is not cost-effective
(Figure 2). For all of the IPT strategies, the predicted number of
DALYs averted is low at low transmission intensities and increases
up to a plateau at moderate levels decreasing slightly at very high
transmission intensities. This slight decrease in DALYs averted at
Figure 2. Predicted number of DALYs averted and cost per DALY averted by transmission intensity. Blue filled circles: year-round IPTc in
children aged 3 months to 5 years, blue hollow circles: seasonal IPTc, red filled triangles: year-round IPTi, red hollow triangles: seasonal IPTi. Top row
(constant transmission): a) DALYs averted and b) cost per DALY averted for IPT with SP c) DALYs averted and d) cost per DALY averted for IPT with
ASAQ. Bottom row (Niakhar seasonality): e) DALYs averted and f) cost per DALY averted for IPT with SP, g) DALYs averted and h) cost per DALY
averted for IPT with ASAQ. The baseline scenario values are given in Tables 1 and 2. Simulated individuals are aged 0–90 years. There is a large degree
of stochasticity in costs per DALY where few DALYs are averted.
doi:10.1371/journal.pone.0018391.g002
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total numbers of DALYs in the scenarios with no IPT. The
predictions suggest that IPTi and IPTc are cost-effective, although
not highly cost-effective, at the low transmission intensities
simulated. With zero transmission, IPT would clearly not be
cost-effective. A clear lower limit below which IPT is not cost-
effective is not obvious: care should be taken with interpretation
since the model was created using data mainly from medium and
high transmission settings and so there is greater uncertainty in
predictions for low transmission intensity settings. The predictions
do however indicate an approximately log-linear relationship.
Since the age-distribution of episodes is affected by transmission
intensity [45,70], the relative impact at a low transmission intensity
was compared for IPTc and IPTi for uncomplicated episodes,
severe episodes and deaths (Figure 3). IPTc averts more clinical
events than IPTi in the simulated scenarios, and the ratio of
clinical events averted by IPTc to IPTi is greater at an EIR of 1
than at an EIR of 21. The size of the ratio, however, depends on
the outcome and the seasonality of the setting.
The predicted number of DALYs averted increased as the
target age group for IPTc was widened to include older children
for all transmission levels simulated (Figure 4, top row), although
the number of DALYs averted per IPT dose decreased. Since the
predictions cover the first ten years of an IPT programme they will
not include potential rebound effects in those receiving IPT for
long periods of time. Increasing the target ages of a five-year wide
age-band for IPTc (Figure 4 bottom row) lead to a decrease in
DALYs averted with increasing age for settings with an EIR of 6
and 21. The scenario with an EIR of 1, however, increased gently
to a maximum at 20 years. This prediction is highly uncertain, and
is driven in the model by the increased surface area of the
individual leading to a higher number of mosquito bites.
Nevertheless, the predictions suggest that IPT would be more
beneficial in older age groups at very low transmission intensities.
Choice of IPT drug
In all of our simulated scenarios, SP averted a greater number of
DALYs and was more cost-effective than ASAQ. This is driven by
the longer prophylactic period of SP, the lower costs and the low
levels of drug resistance we have assumed.
Timing of first dose in seasonal settings
The cost-effectiveness of seasonal delivery of IPTi and IPTc in a
highly seasonal setting is sensitive to the timing of the first dose
(Figure 5). Too early or too late and at least part of the treatment
and prophylactic actions of the drug are wasted. There is some
leeway however and SP was less sensitive to timing than ASAQ
due to the longer prophylactic period. If the three-month delivery
period was begun very early, very few DALYs were averted and
the corresponding costs per DALY were subject to considerable
stochasticity: these values could not be included on the figures.
Whilst the extent of mistiming is unlikely to be three months in
practice, these predictions show that badly timed implementation
can push IPT over the cost-effectiveness threshold.
Proportions of malaria fevers treated
As treatment coverage increases the number of DALYs averted
by IPT decreases and the costs per DALY increase (Figure 6). This
is driven by a reduction in the total DALY burden: the prompt
treatment prevented severe malaria and deaths and cleared
infections which could later produce symptoms and the high
treatment coverage of all age groups lead to a small reduction in
transmission. There was no apparent synergy between health
system coverage and IPT. At very high treatment coverage levels
using ASAQ, some scenarios are no longer cost-effective.
However, this only occurred at treatment levels which would be
unrealistic even for very good health-systems.
Drug Resistance
We simulated the effect of varying levels of drug resistance for
year-round IPTi and seasonal IPTc both with SP only. In both
cases, the number of DALYs averted decreased with rising drug
resistance and the corresponding cost-effectiveness decreased. In
all of the scenarios simulated, IPT remained cost-effective.
However, if a drug has no effect whatsoever, then clearly this
would not be the case [35,71]. We did not simulate levels of
resistance which would render SP completely ineffective. The
linear pattern between DALYs averted and drug sensitivity
(Figure 7a) was also observed for constant seasonality and for
other transmission intensities with an annual EIR of 1 and 200
(not shown).
Impact of IPTi and IPTc on transmission intensity
We predicted a negligible impact of both IPTi and IPTc on the
infectious reservoir and on transmission intensity except where the
wider age groups for IPTc were simulated.
Discussion
The predictions suggest that both IPTi and IPTc are cost-
effective in the majority of scenarios simulated, even with the
conservative thresholds we have used. In general, IPTc averted a
greater number of DALYs than IPTi, but the costs were greater
and consequently the costs per DALY averted were greater. A
greater number of DALYs are averted for both IPTc and IPTi by
year-round compared to seasonal delivery in perennial transmis-
sion settings, but similar numbers of DALYs are averted in
seasonal settings since there are few episodes outside the main
transmission season. Seasonal delivery is more cost-effective in
seasonal settings, and year-round in constant transmission settings.
However the difference is more pronounced for IPTc than IPTi
due to the different proportions of fixed costs and also different
assumed drug spacing during the transmission season. Cost-
effectiveness was predicted to decrease with decreasing transmis-
sion, badly timed seasonal delivery in a seasonal setting, short-
acting and more expensive drugs, increased frequencies of drug
resistance and increasing levels of treatment coverage. A greater
number of DALYs were averted as the target age groups were
widened to include older children for IPTc in all simulated
transmission settings, although the number of DALYs averted per
IPT dose fell slightly. The number of DALYs averted decreased as
the target ages for a five-year age-band were increased except for
very low transmission intensities. This concurs with a systematic
review of the age-distribution of episodes by transmission intensity
in children [70], however the burden in adults is not well
established.
Our aim was not to pit IPTc and IPTi against each other since
they are both interventions focusing on drug administration and
differing only in target age group and delivery system. Instead, we
aimed to tease out the contribution of seasonal delivery in different
settings for both interventions and to investigate factors which
affect their impact and cost-effectiveness. We selected a limited
number of scenarios in order to focus on a manageable number of
questions and to investigate the substantive effects. We recognize
that there are many other potential scenarios differing in
characteristics such as IPT schedule, target age groups, candidate
drugs, seasonal patterns and also equity and heterogeneity in IPT
coverage [45].
Cost-Effectiveness of IPTi and IPTc
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the IPT drug and, in the case of IPTc, delivery since it does not
benefit from the existing delivery strategy EPI. The predicted cost-
effectiveness is driven by the low costs, particularly for IPTi, and
the impact on DALYs, particularly for IPTc. The DALYs were
dominated by the contribution from deaths.
Our predicted costs per episode averted are generally lower
than estimates from clinical trials. The predicted cost per
uncomplicated episode averted ranges from $1.08 to 17.59 for
seasonal IPTc including all the values for transmission intensity
(Figure 3), drug resistance and treatment coverage in comparison
to $22 to $60 per treated episode estimated for district delivery
from trial data [42]. For year-round IPTi with SP, the predicted
cost per episode averted ranges from $0.42 to $7.71 (Figure 3 and
not shown) compared to $1.36 to $11.93 per treated episode from
trial studies [40]. Although our predictions are not of the specific
trials and so differ in many ways, the largest single reason for the
difference is that we have predicted all episodes whereas the trial
data refers to treated episodes only. Our model for acute episodes
[50] is fitted to data from Ndiop and Dielmo in Senegal where
intensive daily active surveillance was carried out [72] thus
capturing episodes unavoidably missed by passive case detection.
The predicted cost-effectiveness of IPTc and IPTi is in line with
other malaria control interventions. Inflating using US dollars only
to US$ 2009, the cost per DALY averted of insecticide-treated net
programmes is estimated to range from $14 to $74 [73–75], and
for indoor residual spraying, US$131–145 [73]. Case management
is estimated to cost between $11 and $31 depending on the
treatment drug and for IPTp estimates vary from $42 to
approximately $422 per DALY averted [74,75].
The question of where the boundaries of IPT cost-effectiveness
lie has been raised, particularly for transmission intensity [43,44].
Our predictions show that, as transmission intensity decreases to
low levels, the number of DALYs averted decreases and the
corresponding cost per DALY increases. Unfortunately, while the
log-linear nature of the relationship is apparent from our
predictions, a boundary where IPTc and IPTi are no longer
cost-effective is not. Even at low transmission intensities, IPT is
predicted to be cost-effective although not highly cost-effective
according to the World Bank thresholds however IPT would
clearly not be cost-effective if there was no transmission. Caution
must be taken with interpreting the predictions for settings with
low transmission intensities since the model was created used data
from mainly medium and high transmission settings and does not
Figure 3. Predicted number of episodes averted and cost per episode averted by transmission intensity. Blue filled circles: year-round
IPTc in children aged 3 months to 5 years, blue hollow circles: seasonal IPTc, red filled triangles: year-round IPTi, red hollow triangles: seasonal IPTi.
The baseline scenario values are given in Tables 1 and 2. Simulated individuals are aged 0–90 years.
doi:10.1371/journal.pone.0018391.g003
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or decay of immunity which may have strong effects in low
transmission settings [52]. In addition, children under five years
old are not predicted to be the optimum target group at very low
transmission intensities and the combination of other factors is
important, for example higher frequencies of drug resistance
would increase the levels of transmission intensity at which IPT is
no longer cost-effective.
Both IPTi and IPTc in children under five years of age were
predicted to have negligible effects on transmission in this study.
This agrees with previous predictions of IPT in these target age
groups [53,76] although simulations of IPTc in children aged 5 to
18 years suggested a reduction in transmission [77]. These results
indicate that a wider target age range including older children
would be necessary to reduce transmission, such as is being
considered for mass screen and treat.
An increased incidence of clinical episodes following the end of
the prophylactic period was observed in some IPTi trials, but not
others [34]. In the seasonal IPTc trials which followed the
participants up over the following season, no rebound effects were
Figure 4. Predicted number of DALYs averted and DALYs averted per dose by IPTc target age group. Light blue circles = EIR 1; mid-
blue diamonds = EIR 6; dark blue squares = EIR 21. Top row (widening age groups): DALYs averted and DALYs averted per dose for constant
seasonality with year-round IPTc a) and b), and Niakhar seasonality with seasonal IPTc c) and d). Bottom row: shifting five-year age-bands.
doi:10.1371/journal.pone.0018391.g004
Figure 5. Predicted effects and cost-effectiveness of IPT depending on timing of first dose in seasonal settings. Blue hollow circles:
seasonal IPTc in children aged 3 months to 5 years, red hollow triangles: seasonal IPTi. Very high and low costs per DALY were not included for early
implementations where the number of DALYs averted were very low since these values were subject to considerable stochasticity. The baseline
scenario values are given in Tables 1 and 2. Simulated individuals are aged 0–90 years.
doi:10.1371/journal.pone.0018391.g005
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indicated a small increase in the incidence of clinical episodes
[39]. A previous study of year-round IPTi predicted a modest
increase in susceptibility following the prophylactic period which
was outweighed by the cumulative benefits [53]. The model would
also predict this same pattern for IPTc doses in older children,
although to a much lesser extent if there is a seasonal break in
transmission. Monthly SP may be akin to chemoprophylaxis [44]
after which rebounds have been observed [78,79]. In practice,
whether IPT equates to chemoprophylaxis would depend on
coverage, the timing of delivery and levels of drug resistance.
Limitations of the model components are discussed elsewhere
[48–53,80–84]. Some assumptions are especially relevant to this
study. The predictions are likely to be sensitive to parameters
relating to age-patterns and outcomes of severe disease in the first
years of life. The predictions of indirect malaria mortality, and to a
lesser extent, severe episodes rely on age-dependent co-morbidity
functions. In a trial setting with access to good health care, the age-
Figure 6. Predicted number of DALYs averted and cost per DALY averted by case-management coverage. Blue filled circles: year-round
IPTc in children aged 3 months to 5 years, blue hollow circles: seasonal IPTc, red filled triangles: year-round IPTi, red hollow triangles: seasonal IPTi.
Top row (constant transmission): a) DALYs averted and b) cost per DALY averted for IPT with SP c) DALYs averted and d) cost per DALY averted for IPT
with ASAQ. Bottom row (Niakhar seasonality): e) DALYs averted and f) cost per DALY averted for IPT with SP, g) DALYs averted and h) cost per DALY
averted for IPT with ASAQ. The baseline scenario values are given in Tables 1 and 2. Simulated individuals are aged 0–90 years.
doi:10.1371/journal.pone.0018391.g006
Figure 7. Predicted impact and cost-effectiveness of IPT by SP drug sensitivity. Blue hollow circles: seasonal IPTc, red filled triangles: year-
round IPTi. SP sensitivity is quantified as the proportion of wildtype infections with no dhfr nutations, with the remainder being divided 50:50
between infections with dhfr single or double and triple mutations. The action of SP varies according to these genotypes (Methods section). The
baseline scenario values are given in Tables 1 and 2. Simulated individuals are aged 0-90 years.
doi:10.1371/journal.pone.0018391.g007
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our models, which were fitted to datasets from other settings [51].
This would affect age-dependent comparisons such as between
IPTc and IPTi, and post-intervention effects. We acknowledge
that a limitation of this study is the lack of a full sensitivity analysis.
We are currently developing an interface which will facilitate
extensive probability sensitivity analyses. Additionally, an ensem-
ble of models with alternative assumptions where uncertainty
exists would provide information on model sensitivity.
The model component for the action of antimalarial drugs was
compatible with our within-host model. The drugs are assumed to
act on the infection, either clearing or sparing it. This model would
be unable to account for observed effects such as density-
dependent cure rate or effects of acquired immunity. More
sophisticated models for within-host parasite dynamics and drug
concentrations are in preparation.
We used DALYs as an aggregate measure to minimise the
number of predictions presented. They are an imperfect measure
and depend on value judgements for the disability weighting,
discounting and age-weighting and on the life table used [85,86].
We followed standard practices, and calculated the DALYs with
no age weighting recognizing that there is a lack of consensus on
this issue [87,88].
The simulations assume a low coverage of case-management
and no other interventions. This is a common approach which
measures the ‘full’ impact of an intervention and offers consistency
when comparing ICERs. However, we recognise decision makers
may already have a variety of interventions in operation and want
to know the incremental benefit of changing their existing status
quo. Model components for other interventions are under
development and these predictions for IPT contribute to a
growing database of the likely effectiveness of different malaria
control strategies generated using a common simulation platform.
When considering IPTc or IPTi for a specific location, both the
local characteristics and issues other than epidemiological impact
and cost-effectiveness should be considered. This study does not
address issues of affordability nor of safety, development of drug
resistance, first line treatment drug choice, sustainability or
malaria species other than P. falciparum.
In conclusion, modelling can extend the information available
to policy-makers by providing predictions of the likely impact and
cost-effectiveness for settings, for outcomes and for multiple
strategies where, for practical reasons, trials cannot be carried out.
Our predictions indicate that both IPTi and IPTc can be cost-
effective interventions in a range of settings. This cost-effectiveness
is driven by low delivery costs and the predicted impact on
mortality. Both IPTi and IPTc could be rendered cost-ineffective
by very low transmission, mis-timed seasonal delivery, ineffective
drugs, very high treatment coverage or combinations of these
factors. Seasonal delivery is more cost-effective in seasonal settings
and year-round in constant transmission settings, the difference is
more pronounced for IPTc than IPTi. Predictions suggested that
the optimum target age group for IPT in settings with a very low
transmission intensity would include children over five years.
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